The inverse relationship between HDL-cholesterol (HDL-C) and cardiovascular (CV) disease risk ( 1 ) suggests that increasing HDL-C could potentially reduce CV risk ( 2 ). This has been postulated to be related to the multiple CV benefi ts of HDL and, perhaps most importantly, the effl ux of cholesterol from peripheral tissue. A variety of agents have been developed that increase HDL-C, including niacin and fi brates, and more recently, agents that decrease cholesteryl ester transfer protein (CETP) activity and are generically referred to as CETP inhibitors.
macrophage RCT. A macrophage RCT model has been extensively characterized (albeit in mice naturally deficient in CETP) and confi rmed as a valid model for assessing promotion of RCT ( 26 ) . In a recent study where torcetrapib was tested in a new hamster macrophage model, although treatment was associated with increased excretion of labeled cholesterol in feces, there was no correlation between fecal sterol excretion and torcetrapib dose. This raised the query as to whether marked inhibition of CETP activity was associated with an increase in HDL of normal composition and function ( 27 ) .
CETP inhibitors represent a valuable tool for investigating the mechanism by which changes in CETP activity affects HDL metabolism in vitro. We therefore compared the potent CETP inhibitors torcetrapib and anacetrapib with the structurally dissimilar benzenethiol derivative dalcetrapib ( 10 ) in terms of respective modes of interaction with CETP, effect on transfer of CE from HDL to LDL versus from HDL3 to HDL2, binding sites, change in CETP conformation, and effect on CETP-induced formation of pre-␤ -HDL. In addition, the potential relevance of these differences was evaluated in vivo by assessing changes in macrophage RCT in CETP inhibitor-treated hamsters.
MATERIALS AND METHODS
All animal studies complied with the guidelines for animal experimentation of our laboratories and were approved by institutional review boards. Human plasma samples were provided by volunteers or were from clinical trials conducted in accordance with the Declaration of Helsinki and approved by independent ethics committees, where participants provided written informed consent.
All compounds studied (dalcetrapib, dalcetrapib-thiol, dalcetrapib-disulfi de, torcetrapib, and anacetrapib) were synthesized using standard procedures. Chemical structures of test compounds are provided (see supplementary Table I ). All additional materials were sourced from recognized suppliers, and commercially available reagents and kits were used according to manufacturers' instructions unless otherwise indicated.
Mode of action
Selective binding of dalcetrapib to Cys13. CETP containing a serine residue instead of Cys13 (C13S CETP) was constructed by site-directed mutagenesis. The protein was expressed in HEK293EBNA cells from large-scale transient transfection, and purifi ed as described below for recombinant human (rh) CETP. 50 ) of dalcetrapib, torcetrapib, and anacetrapib to decrease CE transfer from HDL to LDL by rhCETP and C13S CETP was measured using a scintillation proximity assay kit, #TRKQ7015 (GE Healthcare; Waukesha, WI) ( 28 ) . Briefl y, [ 3 H]CE-labeled HDL donor particles were incubated in the presence of purifi ed CETP proteins (fi nal concentration 0.5 µg/ml) and biotinylated LDL acceptor particles for 3 h at 37°C. Subsequently, streptavidin-coupled polyvinyltoluene beads containing liquid scintillation cocktail binding selectively to biotinylated LDL were added, and the amount of [ 3 H]CE molecules transferred to LDL was measured by ␤ counting.
Inhibition of rhCETP and C13S CETP-mediated transfer of CE from HDL to LDL. The inhibitory potency (IC
at a dose of 600 mg ( 12 ) , is currently being evaluated in a Phase III outcomes study ( 13 ) .
In addition to differences in potency, the mechanism of CETP inhibition by compounds derived from these two chemical classes is also likely to be different. The binding of torcetrapib to CETP increases its affi nity for lipoproteins and induces the formation of an inactive high-affi nity complex between CETP and lipoproteins such as HDL ( 14 ) . The CETP-lipoprotein complex, similar to the one induced by the CETP-inhibitory antibody TP2 ( 15 ), cannot effi ciently exchange neutral lipids between different lipoprotein particles. Although the exact mechanism by which dalcetrapib decreases CETP activity has not been elucidated, the mode of action has been suggested to involve the direct specifi c interaction between cysteine 13 (Cys13) of CETP and the benzenethiol moiety of dalcetrapib ( 9 ) . The thioester bond of dalcetrapib is cleaved by nonspecifi c esterases in the gastrointestinal tract and in plasma, generating reactive dalcetrapib-thiol and allowing formation of a disulfi de bond with Cys13 ( 9 ).
Qiu et al. ( 16 ) suggested that CETP adopts a new conformation to enable binding to lipoproteins of larger size than HDL, such as VLDL. We therefore investigated potential differences in changes in CETP conformation induced by dalcetrapib or torcetrapib using monoclonal antibodies against CETP.
The signifi cance of the different modes of interaction of various CETP inhibitors and the relative impact of decreased CETP activity on lipoprotein metabolism have not been compared previously. Synthetic CETP inhibitors were optimized for the inhibition of neutral lipid transfer between HDL and apolipoprotein B (apoB)-containing lipoproteins (heterotypic transfer), but their effect on transfer of cholesteryl ester (CE) among HDL subparticles (homotypic transfer) and CETP-dependent HDL remodeling have not been studied. CETP facilitates the extensive remodeling of plasma HDL particles by promoting the interconversion of apoA-I-containing ␣ -HDL to small, lipid-poor, pre-␤ -HDL ( 17, 18 ) and transfering CE among HDL subparticles ( 19, 20 ) . This dynamic remodeling of HDL is a key aspect of its function in reverse cholesterol transport (RCT), leading to the removal of excess cholesterol from tissue and its delivery to the liver ( 21 ) . CETP has been shown to impact these two processes by generating small lipid-poor pre-␤ -HDL particles, which are preferred acceptors of ABCA1-dependent cholesterol effl ux ( 22 ) , and to facilitate HDL-CE uptake via the scavenger receptor class B type I (SR-BI) pathway ( 23 ) . In addition, CE transferred by CETP from HDL to LDL and subsequent uptake via the LDL receptor (LDLR) might be an important aspect of RCT ( 24 ) . Thus, the observation that CETP mediates HDL remodeling and cholesterol clearance via the LDLR raised concern that inhibition of CETP activity may adversely impact cholesterol effl ux capacity and RCT ( 21 ) .
Indeed, torcetrapib treatment was not associated with an increase in fecal sterol excretion in clinical studies ( 25 ) , supporting the need for a relevant animal model to investigate the effects of compounds affecting CETP activity on for 3 h at 37°C, then 50 µl of each dilution was analyzed by both types of ELISA.
These ELISAs were applied to plasma samples from 22 healthy subjects receiving a single oral dose of 600 mg dalcetrapib (batch F49, PK study WP22305, Roche data on fi le). Plasma samples were collected before, and 2, 4, 6, 8, 12 , and 24 h after dalcetrapib intake. Dalcetrapib level was measured as described elsewhere ( 36 ) and CETP immunoreactivity was determined using the ELISA described above with JHC-1 or 6/2 as capture antibody and 6/6 or 6/17 for detection. CETP activity was determined by an ex vivo CETP activity assay kit (Roar Biomedical, Inc., New York, NY).
Quantifi cation of pre-␤ -HDL by ELISA. Samples with or without added rhCETP were incubated for 21 h in the presence of torcetrapib, anacetrapib, and dalcetrapib (0.10 µM to 10 µM). Pre-␤ -HDL concentration was measured by ELISA (Daiichi Pure Chemicals Co. Ltd, Tokyo, Japan) as previously described ( 37 ) .
Additional methodology relating to characterization of pre-␤ -HDL by SEC/reverse-phase protein array and the assessment of pre-␤ -HDL generation by Western blot are provided as supplementary materials.
Statistical analysis was performed by an ANCOVA model in which the slope of pre-␤ -HDL formation as a function of CETP concentration was compared between the tested doses of each compound.
In vivo RCT study. To investigate the effect of dalcetrapib, torcetrapib, and anacetrapib on macrophage-to-feces RCT, radiolabeled macrophages from the peritoneal cavity of donor Golden Syrian hamsters preinjected with [ 3 H]cholesterol were prepared as previously described ( 38 6 cells/90.6 kBq/0.5 ml per animal) at day 0. The percentage of esterifi ed cholesterol in injected macrophages was 21% (mass) and 16% (labeled). Animals continued to receive vehicle or test compounds daily for 10 days. Samples for plasma lipid analysis were obtained on days Ϫ 7, 0, 3, 7, and 10 and for radioactivity levels on days 3, 7, and 10. Total cholesterol and HDL-C were measured by enzymatic methods (Roche Diagnostics, Burgess Hill, West Sussex, UK). HDL-C was measured as the cholesterol concentration in the HDL fraction separated by polyethylene glycol 6000 solution. The area under the plasma HDL-C concentration-time curve (HDL-C·AUC) during the RCT study period (day 0 to day 10) was calculated from plasma HDL-C levels (at day 0, 3, 7, and 10) by the trapezoidal method.
Feces were collected continuously from day 0 to day 10. Fecal neutral sterols were extracted by a 2:1 mixture of chloroformmethanol ( 39 ) ( 40 ) . Fecal bile acids extracted by ethanol were measured by an enzymatic method (Wako Pure Chemical Industries Ltd, Osaka, Japan).
Additional methodology relating to the measurement of fecal sterols is provided in Supplementary Materials.
Statistical analysis
The relationship between dose of CETP inhibitor and pre-␤ -HDL formation was assessed by ANCOVA with nested factor (PROC MIXED from SASv8) and on CE transfer from HDL3 to HDL2 by Student's t -test or Dunnett test.
For RCT studies, differences between control and test compound groups were assessed using the Bartlett test followed by Inhibition of transfer of CE from HDL3 to HDL2. Assessment of lipid movement among HDL subfractions was performed using radiolabeled lipid transfer assays as previously described ( 20 ( 29 ) . [ 3 H]CE-labeled HDL3 and nonradiolabeled HDL2 (1.063 < d < 1.125 g/ml) were added on an equal phospholipid basis (2.3 g/tube). The lipoprotein mixture was incubated in the presence of 1% BSA, 21 mM trisHCl (pH 7.4), 0.5% NaCl, and 0.006% EDTA with or without rhCETP (0.5 g/tube). Dalcetrapib, torcetrapib, and anacetrapib were tested at concentrations of 0.001, 0.01, 0.1, 1, and 10 µM in a total volume of 0.715 ml and incubated for 4 h at 37°C. After incubation, HDL2 and HDL3 fractions were separated by ultracentrifugation (d = 1.125 g/ml) for 19 h at 4°C. Total radioactivity in the HDL2 (upper layer) and HDL3 (lower layer) subfractions was measured by scintillation counting. CETP activity was expressed as the percentage of total radioactivity recovered in the HDL2 fraction.
Binding sites of compounds on CETP: competition for binding site on sepharose-immobilized rhCETP.
Binding studies were performed according to Connolly et al. ( 30 ) using rhCETP expressed by a cell line described by Weinberg et al. ( 31 ) , kindly provided by Professor Alan Tall (Columbia University) and purifi ed by hydrophobic interaction chromatography and size exclusion chromatography (SEC) [modifi ed from Ohnishi, Yokoyama, and Yamamoto ( 32 )]. BSA and rhCETP were immobilized on CNBr-activated sepharose 
Changes in conformation of CETP assessed by ELISA. ANTI-CETP
ANTIBODY PRODUCTION . Antibodies were raised in NMRI mice injected intraperitoneally with 20 µg rhCETP emulsifi ed in aluminum hydroxide gel (Alhydrogel-2%; Brenntag Biosector, Frederikssund, Denmark) containing CpG oligodeoxynucleotides according to Davis et al. ( 33 ) . The animals received four booster injections each at 3-week intervals with the same antigen preparation.
As soon as the animals showed a specifi c immune response to the rhCETP, the best responders were boosted, and after 3 days, the spleens were removed and the isolated cells were fused to PAI myeloma cells, a variant of the P3-x63-AG8 myeloma ( 34 ) . The monoclonal antibodies 6/2, 6/6, and 6/17 were selected for further characterization, together with clone JHC-1 ( 35 ) .
CETP ELISA USING DIFFERENT CAPTURE ANTIBODIES . Two types of
ELISA were performed, one using clone JHC-1 as capture antibody and clone 6/6 conjugated to HRP as detection antibody, and the other with clone 6/2 as capture antibody and clone 6/17 conjugated to HRP as detection antibody.
In vitro addition of CETP inhibitors: plasma samples from seven healthy donors were prediluted 1:10 with blocking buffer (50 mM Tris, 140 mM NaCl, 5 mM EDTA, 0.05% Nonidet P40, 0.25% gelatin, 1% BSA, pH 7.4). A dilution series of the test compounds was prepared from this prediluted plasma and incubated monoclonal antibodies were produced in an attempt to select those directed toward epitopes potentially modifi ed following the binding of different CETP inhibitors. Binding characteristics of capture antibodies JHC-1 and 6/2 to rhCETP were established by surface plasmon resonance (SPR). The association rate constant ( k a ) of the antibody JHC-1 was 3. Table IIC) .
The antibody JHC-1 was selected as a capture antibody for development of an ELISA to detect an epitope selective the Steel test. The Dunnett test was applied when no differences were found with the Bartlett test. Differences were considered signifi cant when P < 0.05 (two-sided).
RESULTS

Mode of action
Role of CETP Cys13 in the inhibitory activity of dalcetrapib versus torcetrapib and anacetrapib toward CE transfer from HDL to LDL. It was shown previously that mutation of Cys13 to Ser (C13S), but not mutation of Cys1 or Cys131, abolishes the CETP inhibitory activity of dalcetrapib ( 9 ) . Using a synthetic assay system, we determined the IC 50 of torcetrapib, anacetrapib, and dalcetrapib for transfer of CE from HDL to LDL by rhCETP and C13S CETP mutant. In this assay system, the mean ± SEM IC 50 of dalcetrapib, dalcetrapib-thiol, and dalcetrapib-disulfi de was found to be 204.6 ± 96.3 nM, 23.7 ± 1.9 nM, and 35.2 ± 2.8 nM, respectively, for rhCETP, whereas this was >100,000 nM for the same compounds for the C13S CETP mutant. Torcetrapib and anacetrapib were potent inhibitors of rhCETP with an IC 50 of 7.4 ± 2.6 nM and 7.9 ± 2.5 nM, respectively, while their inhibitory activity was virtually unchanged for the C13S CETP mutant (11.8 ± 5.2 nM and 11.8 ± 1.9 nM, respectively).
Differential inhibitory activity of dalcetrapib, torcetrapib, and anacetrapib toward CE transfer from HDL3 to HDL2. Dalcetrapib was fi rst tested at concentrations of 0.01, 0.1, 1, and 10 M for its effect on CE transfer from HDL3 to HDL2. As displayed in Fig. 1A , no effect of dalcetrapib was observed up to 10 M. In a second series of experiments, torcetrapib and anacetrapib were tested at 0.001, 0.01, 0.1, 1, and 10 M, and dalcetrapib at 1 and 10 M. As shown in Fig. 1B , torcetrapib and anacetrapib dose-dependently and signifi cantly decreased the transfer of CE from HDL3 to HDL2 ( P < 0.001 for concentrations equal to and higher than 0.1 µM), which remained unchanged with dalcetrapib at concentrations of 1 and 10 µM. CETP activity and correlated with the reduction in CETP activity ( Fig. 3D ) . As expected, no change was detected in the same plasma when 6/2 was used as capture antibody. In the same subjects, the plasma dalcetrapib-thiol level reached a maximum of 628.7 ng/ml at 4 h ( Fig. 3E ) , the mean ± SD t 1/2 of 25.5 ± 3.9 h suggesting that the induced change in conformation was maintained at low plasma dalcetrapib concentrations, as evidenced at the 12 h time point.
Competition for binding to rhCETP of
In vitro generation of pre-␤ -HDL by CETP in human plasma: effect of CETP inhibitors. In vitro incubation of human plasma with added increasing concentrations of purifi ed rhCETP led to a dose-dependent increase in lipid-poor apoA-I-containing particles (SEC fraction 29), characterized as pre-␤ -HDL by agarose gel electrophoresis (see supplementary Fig. I ).
Quantifi cation of pre-␤ -HDL by ELISA. To better evaluate the role of CETP in the generation of pre-␤ -HDL in human plasma, and to quantify the amount of pre-␤ -HDL generated, we incubated human plasma with or without added rhCETP and quantifi ed pre-␤ -HDL by a pre-␤ 1-selective ELISA. Incubation of human plasma for 21 h at 37°C without added exogenous CETP, increased the level of pre-␤ -HDL by 43%. Dalcetrapib 1, 3, and 10 M dosedependently increased pre-␤ -HDL by 4, 13, and 16% (NS, P < 0.05, P < 0.01, respectively). Torcetrapib and anacetrapib decreased pre-␤ -HDL formation by more than 46% ( P < 0.001) at all concentrations tested ( Fig. 4A ) .
The dose-related effect of dalcetrapib, torcetrapib, and anacetrapib on the amount of pre-␤ -HDL at different concentrations of added rhCETP was evaluated. Data were analyzed by an ANCOVA model in which slopes of pre-␤ -HDL as a function of CETP were compared between doses by compound. A statistically signifi cant increase in pre-␤ -HDL formation was observed with dalcetrapib ( P < 0.001, 0.001, 0.05, and 0.001 for concentrations of 0.1, 1, 3, and 10 M, respectively) ( Fig. 4B ). In the case of torcetrapib, a dosedependent decrease in pre-␤ -HDL formation was observed even at the lowest concentration of 0.1 M ( P < 0.004), and at 1, 3, and 10 M (each P < 0.001) ( Fig. 4C ) . Similar reductions in pre-␤ -HDL formation were observed for anacetrapib at 1, 3, and 10 M (each P < 0.001) ( Fig. 4D ) .
In vivo RCT study. EFFECT OF DALCETRAPIB, TORCETRAPIB, AND ANACETRAPIB ON RCT IN HAMSTERS.
Pilot dose-response studies with dalcetrapib, torcetrapib, and anacetrapib showed that dalcetrapib 100 mg/kg BID, torcetrapib 30 mg/kg QD, and anacetrapib 30 mg/kg QD provided similar reductions in the area under the concentration time curve AUC 0-24 (% transfer·h) for CETP inhibitory activity although HDL-C levels were not comparable (data not shown). These doses were therefore selected for in vivo RCT studies in hamsters to assess if differences among the three compounds observed in vitro would manifest as differences in macrophage RCT. Hamsters were given dalcetrapib, torcetrapib, or anacetrapib for 7 days before injection of [ 3 H]cholesterol-labeled macrophages (day 0). Treatment with dalcetrapib, torcetrapib, or anacetrapib for the dalcetrapib-CETP interaction, whereas antibody 6/2 was used as capture antibody for the reference ELISA. Plasma samples from seven healthy volunteers were incubated in vitro with dalcetrapib and torcetrapib (0.01 µM to 10 µM). Using antibody 6/2, no change in epitope detection was observed with concentrations of dalcetrapib and torcetrapib up to 10 µM ( Fig. 3A ) . On the contrary, dalcetrapib decreased CETP detection by JHC-1 starting at a concentration of 0.1 µM ( Fig. 3B ) . Torcetrapib did not change epitope detection by JHC-1 antibody over the concentration range 0.01 µM to 10 µM ( Fig. 3B ) .
Change in conformation of CETP in plasma samples from volunteers receiving a single 600 mg oral dose of dalcetrapib assessed by ELISA.
A decrease in CETP detection by the JHC-1-based ELISA was also observed in plasma from 22 healthy volunteers who received a single oral dose of 600 mg dalcetrapib (30%, P < 0.001), confi rming in the clinical setting the change in epitope detection by JHC-1 induced by dalcetrapib in vitro ( Fig. 3C ) . In addition, the decrease in detection of CETP by JHC-1 antibody paralleled that of labeled) was signifi cantly increased only in the dalcetrapib group. For anacetrapib, there were no signifi cant changes in any of the fecal parameters described in Table 2 , compared with control. We evaluated the relationship between HDL-C raised by dalcetrapib, torcetrapib, or anacetrapib for the RCT observation period (day 0 to day 10), RCT promotion by calculating the HDL-C·AUC over 0 to 10 days, and also fecal total radioactive sterols for each compound, as shown in Fig. 5 . It can be seen that dalcetrapibtreated hamsters had the highest fecal radioactivity despite a lower HDL-C·AUC than torcetrapib and anacetrapib. In the absence of signifi cant and consistent changes in the expression of genes involved in hepatic and adipose tissue lipid metabolism (hepatic: CETP, apoA-I, apoB, apoE, CYP7A1, CYP8B1, HMG-CoA reductase, LDLR; adipose tissue: CETP, apoA-I, apoE, SR-BI) for all treatment groups, we consider the differences observed with the three CETP inhibitors to be more related to their effect on led to signifi cant increases in HDL-C levels at day 0 ( Table  1 ). The effi cacy of dalcetrapib appeared to be less than that of torcetrapib and anacetrapib. At day 3, [
3 H]cholesterol radioactivity in the HDL fraction was signifi cantly increased from control values for dalcetrapib, torcetrapib, and anacetrapib ( Table 1 ) .
At the end of the study (day 10), liver radioactivity was signifi cantly reduced by dalcetrapib and torcetrapib compared with vehicle ( Ϫ 42.2% and Ϫ 28.1%, respectively; both P < 0.01), whereas the reduction with anacetrapib ( Ϫ 9.2%) was not statistically signifi cant (data not shown). Total fecal radioactivity over the period from day 0 to day 10 was signifi cantly increased versus control in dalcetrapiband torcetrapib-treated animals ( Table 2 ). Although torcetrapib signifi cantly increased only the radioactivity of fecal bile acids and not fecal neutral sterols, dalcetrapib significantly increased the radioactivity of both components. Moreover, the mass of total fecal bile acids (nonradio- target CETP activity. We compared compounds representative of the main chemical classes, the 3,5-bis-trifl uoromethyl-benzene derivatives torcetrapib and anacetrapib, and the benzenethiol derivative dalcetrapib, for biochemical characteristics underlying their interaction with CETP, and for their effect on CETP-induced pre-␤ -HDL formation and RCT in vivo in a macrophage-to-feces RCT hamster model.
Mechanisms leading to a decrease in CETP activity
Several thiol-containing compounds have previously been shown to affect CETP activity ( 11 ) via an interaction plasma lipoproteins than on hepatic lipid metabolism (see supplementary Table IIIB) .
DISCUSSION
Although CETP inhibition is an accepted means to reproducibly increase plasma HDL-C, the mechanism and extent of inhibition required to optimally increase HDL and maintain HDL functionality has proven controversial and, to date, inadequately addressed. We attempted to resolve this by taking advantage of the availability of agents derived from different chemical classes that specifi cally SPR investigations confi rmed that the binding of dalcetrapib-thiol to the CETP C13S mutant was negligible when compared with rhCETP (see supplementary Fig. II ) . As reported, a single peptide with dalcetrapib-thiol bound to Cys13 was identifi ed by mass spectrometry (data not shown). The binding of dalcetrapib-thiol to Cys13 could prevent its potential critical interaction with Cys1 and/or Cys333 as observed by Hope et al. ( 42 ) .
As expected, torcetrapib was shown to interact similarly with rhCETP and the C13S CETP mutant, excluding a potential interaction with Cys13 as a major mechanism associated with CETP inhibition by torcetrapib and torcetrapib-related compounds. The monitoring of binding interactions, kinetic rate constants, and thermodynamic parameters in real time by SPR further confi rmed this fi nding, inasmuch as following saturation of the dalcetrapib binding site (see supplementary Fig. III ) the binding of torcetrapib remained unchanged.
We observed a decreased binding affi nity of the anti-CETP monoclonal antibody JHC-1 to CETP incubated with dalcetrapib-thiol, as judged by SPR. Because JHC-1 does not bind to dalcetrapib-thiol, and does not bind to any cysteine-containing polypeptide of CETP, as judged by SPR (see supplementary Table IIC) , these results support the hypothesis that the binding of dalcetrapib changes exposure of the epitope recognized by the JHC-1 antibody. An ELISA using JHC-1 as a capture antibody confi rmed a with free cysteine residues of CETP that play an important role in its transfer activity ( 41 ) . In agreement with previous studies ( 9 ), the benzenethiol derivative dalcetrapib decreased CETP activity, measured as transfer of CE from HDL to LDL of wild-type rhCETP, but did not inhibit CETP activity of the C13S mutant (IC 50 of 204.6 ± 96.3 and >100,000 nM, respectively). On the contrary, both torcetrapib and anacetrapib were active and equipotent for recombinant wild-type and the C13S CETP mutant (IC 50 of 7.4 ± 2.6 and 11.8 ± 5.2 nM, respectively, for torcetrapib and 7.9 ± 2.5 and 11.8 ± 1.9 nM, respectively, for anacetrapib).
Surprisingly, dalcetrapib at concentrations up to 10 M did not affect homotypic CE transfer from HDL3 to HDL2. Such transfer was potently inhibited by torcetrapib and anacetrapib at concentrations equal to and higher than 0.1 M, suggesting that dalcetrapib, by not interfering with transfer among HDL subparticles, is more likely a modulator than an inhibitor of CETP activity and that dalcetrapib may interact with and decrease CETP activity by a unique mechanism.
Competitive binding studies showed that torcetrapib and anacetrapib decreased binding of radiolabeled [ 14 C]torcetrapib to CETP, whereas dalcetrapib, dalcetrapib-thiol, or dalcetrapib-disulfi de had no, or only a marginal, effect. Conversely [ 14 C]dalcetrapib-thiol bound to CETP was displaced in the presence of reducing agent by dalcetrapib and dalcetrapib-thiol but not by torcetrapib and anacetrapib. Comparison of the effect of dalcetrapib, torcetrapib, and anacetrapib on HDL-C·AUC and radioactivity of fecal total sterols as a percentage of injected radioactivity in the hamster macrophage reverse cholesterol transport (RCT) study. HDL-C·AUC during the RCT study period was calculated from plasma HDL-C levels (day 0, 3, 7, and 10) by the trapezoidal method. Error bars represent the SD for n = 5 or 6 animals. * P < 0.01 (HDL·AUC); # P < 0.01 (radioactivity of fecal total sterols) vs. control (Dunnett test).
CETP has been shown in experiments using a purifi ed HDL fraction (i.e., in the absence of LDL and VLDL) to be involved in lipid transfer among HDL particles, and also to play an important role in HDL remodeling and the generation of pre-␤ -HDL ( 17, 18, 48, 49 ) . The increase in pre-␤ -HDL, measured by a specifi c and sensitive ELISA detecting a specifi c epitope exposed only in pre-␤ 1-HDL ( 37 ) following incubation of human plasma, is most likely generated by endogenous CETP, inasmuch as it is abolished by the two CETP inhibitors torcetrapib and anacetrapib. A similar inhibition of pre-␤ -HDL formation using the monoclonal antibody TP1 to inhibit CETP activity was fi rst described by Lagrost et al. ( 49 ) , albeit using a purifi ed HDL fraction. Surprisingly, in contrast to torcetrapib and anacetrapib, dalcetrapib up to 10 µM did not prevent pre-␤ -HDL formation produced by endogeneous CETP but signifi cantly increased pre-␤ -HDL generation. Pre-␤ -HDL formation induced by rhCETP (4 to 25 times normal CETP level) added to human plasma was also dose-dependently and markedly decreased by torcetrapib and anacetrapib, whereas such an effect was not observed with dalcetrapib. These differences could be linked to the strong inhibitory effect of torcetrapib and anacetrapib on CE transfer from HDL3 to HDL2, which is absent with dalcetrapib.
Phospholipid transfer protein (PLTP) has also been shown to play an important role in HDL remodeling ( 50 ) . Because dalcetrapib (data not shown) and torcetrapib ( 14 ) neither inhibit nor increase PLTP activity at concentrations up to 30 M, we conclude that in human plasma CETP is a major component of HDL remodeling and that this process is highly sensitive to nonselective or potent CETP inhibitors.
Our fi ndings suggest that, in contrast to both torcetrapib and anacetrapib, dalcetrapib may behave like a direct CETP modulator ( 20, 51 ) in not affecting CETP activity among HDL particles and preserving pre-␤ -HDL formation, thus, potentially maintaining or enhancing the fi rst step of RCT.
To determine the potential biological relevance of the biochemical differences described above, the impact of the three agents affecting CETP activity on macrophage RCT was assessed in vivo using a hamster model ( 27 ) derived from the well-characterized mouse model ( 26, 52 ) . In contrast to mice, hamsters express CETP endogenously and have been used previously to study the effect of CETP inhibition on plasma lipoproteins ( 53 ) . We further developed this model by using in vivo [ Although dalcetrapib provided a relatively smaller increase in HDL-C than did torcetrapib and anacetrapib, it was the most effective in promoting fecal excretion of macrophage [ 3 H]cholesterol, mainly as bile acids. In addition, only dalcetrapib was shown to increase total fecal bile acid mass, which may be due to a higher turnover of HDL-C. Indeed, Schwartz et al. ( 54 ) showed in humans that HDL-C is preferentially used for bile acid synthesis, whereas Nanjee and coworkers showed that infusion of apoA-I in man generates pre-␤ -HDL and increases bile acid elimination marked decrease in the detection of this epitope in human plasma incubated with increasing concentrations of dalcetrapib (0.01 µM to 10 µM), with a maximum effect reached at 0.5 µM. The relevance of this fi nding to the clinical situation was examined using plasma samples from 22 healthy volunteers who each received a single oral dose of 600 mg dalcetrapib. A highly signifi cant decrease in the detection of the JHC-1-specifi c epitope was observed at 4, 6, 8, and 12 h postdose at plasma levels of dalcetrapib-thiol between 200 and 700 ng/ml (0.63 µM to 2.2 µM). These observations support the hypothesis of a change in conformation of CETP upon binding of dalcetrapib-thiol to Cys13 in vitro and in vivo at therapeutic concentrations. It should be noted that in spite of the covalent nature of the binding of dalcetrapib-thiol to CETP and potentially to other plasma proteins ( 43 ) , the compound is cleared with a relatively short half life (t 1/2 25.5 h), and the resulting decrease in CETP activity and change in conformation are only transient. The results indicate that the covalent binding of dalcetrapib is weak and fully reversible. The observed correlation between the change in conformation and the decrease in CETP activity suggests that dalcetrapibthiol binding to CETP could impair or limit the changes in conformation needed for the optimal activity of CETP, i.e., in accordance with the model of Bruce, Beamer, and Tall ( 44 ) or the specifi c increase in curvature suggested by Qiu et al. ( 16 ) to be required for binding to VLDL.
Although potent or nonselective CETP inhibitors may affect transfer among all lipoproteins and subparticle classes, the dalcetrapib-dependent conformational change of CETP may lead to a modulation of CETP activity, decreasing neutral lipid transfer between HDL and LDL (heterotypic transfer) while preserving transfer between other lipoprotein classes, such as between HDL3 and HDL2 (homotypic transfer) ( 45 ) . Change in CETP conformation induced by dalcetrapib could also explain the subsequent decrease in the binding of the torcetrapib analog by hindrance of its binding site under the experimental conditions used by Cunningham et al. ( 46 ) .
Of the seven cysteines of human CETP, only two are involved in stable S-S bond formation (Cys143 and Cys184). The presence of the fi ve additional cysteines suggests that some might be involved in the allosteric regulation of CETP activity. Indeed, it has been demonstrated that modifi cation of the N-terminal Cys1 of CETP is involved in the selective inhibition of triglyceride versus CE transfer activity ( 47 ); on the contrary, selective inhibition of CE transfer can be achieved by compounds binding to Cys333 ( 41 ) . These data suggest that both Cys1 and Cys333 are involved in the selective transfer of neutral lipids. We may hypothesize, therefore, that Cys13 plays a role different from that of either Cys1 or Cys333 in modulating CETP activity by facilitating or preventing the transfer of neutral lipids between lipoproteins of selective size and/or composition, as illustrated in Fig. 6 .
CETP-induced pre-␤ -HDL formation
In addition to its well-established role in the transfer of neutral lipids from HDL to apoB-containing lipoproteins, transfer. In addition, we have shown that dalcetrapib induces a specifi c conformational change of CETP not observed with torcetrapib. These different modes of action have opposing effects on the in vitro process of HDL remodeling and pre-␤ -HDL generation, which is important in HDL-induced RCT and may explain the stronger effect of dalcetrapib on in vivo RCT in hamsters. These results suggest that compounds originally described as CETP inhibitors can be differentiated into CETP modulators such as dalcetrapib, and CETP inhibitors exemplifi ed by torcetrapib. The clinical relevance of these in vitro properties, and the differences observed in macrophage RCT in hamsters, remains to be determined. The ongoing Phase III placebo-controlled dal-OUTCOMES study ( 13 ) evaluating the effect of 600 mg dalcetrapib in clinically stable patients (n = 15,600) following a recent acute coronary syndrome will provide more information as to the clinical signifi cance of modulation of CETP activity by dalcetrapib. ( 55 ) . This is the fi rst report, to our knowledge, in which an agent targeting CETP activity is shown to affect macrophage RCT. In accordance with previous studies of torcetrapib ( 27 ) , a weak increase in RCT was observed, whereas we found that anacetrapib treatment had no effect, despite being associated with the greatest increase in HDL-C levels. In addition, a dose-response study with dalcetrapib confi rmed the absence of any correlation between [ 3 H]HDL-C levels and fecal elimination of labeled sterols (data not shown).
These fi ndings are consistent with the hypothesis that direct modulation of CETP activity by dalcetrapib increased RCT in vivo by maintaining pre-␤ -HDL formation and CE transfer between HDL subparticles, thus preserving the fi rst step of RCT: effl ux from peripheral tissues via the ABCA1 transporter. Interestingly, it has been proposed by Morton and Greene ( 51 ) that apoF acts as a physiologic CETP modulator by preferentially diminishing transfer events involving LDL, especially those between VLDL and LDL, and indirectly enhancing the ability of CETP to remove CE from HDL subparticles and to remodel HDL. For these reasons, the authors suggested that modulation of CETP activity by apoF could be a very effi cient way to increase RCT ( 20, 51 ) .
In summary, we have demonstrated that compounds that decrease CETP activity, derived from two different chemical classes, have different binding sites to CETP and differentially affect homotypic and heterotypic CE 
